U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H16N2S
Molecular Weight 280.387
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FANETIZOLE

SMILES

C(CC1=CC=CC=C1)NC2=NC(=CS2)C3=CC=CC=C3

InChI

InChIKey=WEEYMMXMBFJUAI-UHFFFAOYSA-N
InChI=1S/C17H16N2S/c1-3-7-14(8-4-1)11-12-18-17-19-16(13-20-17)15-9-5-2-6-10-15/h1-10,13H,11-12H2,(H,18,19)

HIDE SMILES / InChI

Molecular Formula C17H16N2S
Molecular Weight 280.387
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Fanetizole is a derivative of 2-aminothiazole. It is an anti-inflammatory agent. This drug is reported to have some cyclooxygenase inhibiting activity. Production of superoxide in response to the chemotactic factor formyl-methionyl-leucyl-phenylalanine (f-Met-Leu-Phe) was markedly inhibited by fanetizole. Suppression of neutrophil production of toxic oxygen metabolites may partially explain the antiarthritic effect of fanetizole. Fanetizole was shown to restore depressed E-rosetting activity in adult thymectomized mice, as well as enhance in in vitro proliferation of murine thymic cells to mitogen and synergistically acted with the monokine interleukin-1. It displays anti-arthritic activity in viva in the rat adjuvant arthritis model, inhibiting the development of disease in the non-infected foot. This drug has less side effects than levamisole in animals.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
B cells from 16 atopic subjects without eczema produced de novo a mean of 516 pg/ml of IgE without the drug and 196 pg/ml in the presence of 2.5 x 10(-4) M drug. B cells from 6 atopic subjects with eczema synthesized a mean of 1984 pg/ml of IgE in the absence of the drug and 1486 pg/ml in the presence of 2.5 x 10(-4) M drug.
Substance Class Chemical
Record UNII
BH48F620JA
Record Status Validated (UNII)
Record Version